Last Updated: May 20, 2026

Claims for Patent: 9,309,315

✉ Email this page to a colleague

Summary for Patent: 9,309,315

Title:	Therapy with CD4 binding peptides and radiation
Abstract:	The present invention relates to a peptide, such as an antibody, capable of binding to CD4 and use thereof for the mediation of radiation treatment of a clinical condition. The radiation treatment may for instance by treatment with PUVA.
Inventor(s):	Paul Parren, Ole Baadsgaard, Denis Alexander
Assignee:	Genmab AS
Application Number:	US11/990,581

Details for Patent 9,309,315

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	December 23, 2013	⤷ Start Trial	2026-08-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,309,315

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2007019865	⤷ Start Trial
United States of America	2010015134	⤷ Start Trial
New Zealand	594784	⤷ Start Trial
New Zealand	566520	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.